Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Rhinosinusitis
Asthma
Nasal Polyps
Polyps


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Primary Objective

-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell

Secondary Objectives

* To evaluate the efficacy of dupilumab in improving chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms at Week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24 compared to omalizumab * To evaluate the safety of dupilumab and omalizumab

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2021 Oct 2024

Publications

"De Prado Gomez PharmD MSc L, Khan Mbbs Mph AH, Peters Md AT, Bachert Md PhD C, Wagenmann Md M, Heffler Md PhD E, Hopkins BMBCh C, Hellings Md PhD PW, Zhang PhD M, Xing PhD J, Rowe Md P, Jacob-Nara Md Mph DHSc JA. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. Am J Rhinol Allergy. 2022 Nov;36(6):788-795. doi: 10.1177/19458924221112211. Epub 2022 Jul 15."; "35837739"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : solution for injection subcutaneous

Intervention Arm Group : Dupilumab;

Intervention Type : DRUG
Intervention Description : solution for injection subcutaneous

Intervention Arm Group : Omalizumab;

Intervention Type : DRUG
Intervention Description : solution for injection subcutaneous

Intervention Arm Group : Dupilumab;Omalizumab;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Investigational Site Number : 8260003
    Wigan
    Lancashire
    WN6 9EP
  • Investigational Site Number : 8260002
    Manchester
    M23 9LT
  • Investigational Site Number : 8260001
    Newcastle Upon Tyne
    NE7 7DN


The study is sponsored by Sanofi and is in collaboration with Regeneron Pharmaceuticals.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT04998604
Last updated 27 August 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.